BioWorld Asia

March 29, 2006

NicOx Expands Merck Deal For Up To $350M

A research collaboration that started in August 2003 came full circle when French company NicOx SA granted Merck & Co. Inc. exclusive worldwide development and marketing rights to nitric oxide-donating drugs for hypertension. (BioWorld International) Read More

Pharming Acquiring DNAge: Milestones, EUR15M In Shares

Mutant Yeast Show Details Of Telomere Maintenance

Europe’s Biotech Industry Energized By EU Summit

PanGenetics Brings In EUR13M For Antibody Development

Pfizer Licenses, Invests In Noxxon’s Spiegelmer Drugs

Biotech Pipelines Sitting Unexploited’ In Australia

Speedel Raises CHF79.7M In Sale Of Treasury Shares

BioSystems Licenses Biomarker Technology From Northeastern

Diagnostics Seen As Hope For Future Of Health Care

Biofusion, NPI Set UP £10M Fund To Fuel Biotech Firms

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

University of Southern California reports new MAPT aggregation inhibitors

BioWorld Science

The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...